HCPCS Level II code J1559 identifies a 100 mg unit of Hizentra, a subcutaneous immune globulin preparation used for immunodeficiency and certain autoimmune indications. Nationally, this code matters for accurate drug-specific billing, dose-based reimbursement, and distinguishing subcutaneous immune globulin from intravenous formulations. It also affects charge capture and inventory management for providers administering Hizentra in outpatient and home settings.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find an overview of the code’s clinical context, typical sites of service, and the payers most commonly engaged in coverage and payment decisions. The publication also summarizes available benchmarks for utilization and claims coding practices, notes relevant policy and coverage considerations, and highlights areas where coding specificity can influence payment and reporting.

Content is designed to inform billing staff, revenue cycle leaders, and clinical managers about billing precision for subcutaneous immune globulin, interpretation of HCPCS Level II coding for Hizentra, and where to look for payer policy differences and documentation expectations. Data not available in the input is identified where applicable.